Epigral Limited (EPIGRAL) Fair Value & Analysis
Basic Materials · IN · Market cap ₹47.7B
Fair value as of: Jun 29, 2026
Analysis
Epigral Limited (EPIGRAL) currently trades at ₹1,106, while our model-based Fair Value estimate is ₹1,144 — implying the stock looks roughly 3.4% undervalued today. We read business quality at 97/100 (high quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Epigral Limited manufactures and sells chlor-alkali and derivative products in India and internationally. The company offers chlorinated polyvinyl chloride (CPVC) resin, epichlorohydrin, chloromethanes value chain, hydrogen peroxide, caustic soda and potash, chlorine, hydrogen, chloromethanes, captive power plant (CPP), and chlorotoluene value chain, as well as operates wind-solar hybrid power plant. Its products are used in CPVC pipes and fittings, windmills, construction, paints and coatings, electronics, water treatment, agrochemicals, pharmaceuticals, refineries, soap and detergents, fluoropolymers, paper and pulp, textiles, alumina, polyurethane foam, lithium, and polytetrafluoroethylene (PTFE) pipes. The company was formerly known as Meghmani Finechem Limited and changed its name to Epigral Limited in August 2023. Epigral Limited was incorporated in 2007 and is based in Ahmedabad, India.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Epigral Limited (EPIGRAL) undervalued?
What is the fair value of EPIGRAL?
What is the quality score of EPIGRAL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.